Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Research Article

Association of CA 15-3 and CEA with Liver Metastases in Patients with Breast Cancer

Author(s): Akram Yazdani* and Hossein Akbari

Volume 16, Issue 4, 2020

Page: [332 - 336] Pages: 5

DOI: 10.2174/1573394716666191216112938

Price: $65

Abstract

Objective: The liver is the second most common site of distant metastasis from breast cancer that is usually associated with poor prognosis and low quality of life in breast cancer patients. Therefore, the primary diagnosis of liver metastatic lesions in breast cancer patients is very important. In this study, the ability of biochemical markers CA153, CEA, and ALP to be used for prognostic liver metastasis in women with breast cancer was investigated.

Methods: 306 women with breast cancer recorded between 2008 and 2012 were included. Serum concentrations of alkaline phosphatase (ALP), carcinogenicity antigen (CEA), cancer antigen (CA-153), age, menopausal status, histologic type, tumor size and number of cancerous axillary lymph nodes in two groups of breast cancer women with liver metastases and without it were studied. To identify independent liver metastasis prognostic factors, logistic regression method was applied.

Results: The independent prognostic factors of liver metastases in women with breast cancer are ALP, CEA, age, menopausal status, number of cancerous axillary lymph nodes and tumor size. Sensitivity and specificity analysis showed that CEA with a cutoff value of 1.1 was the most accurate predictive factor.

Conclusion: The increase in the levels of CEA and ALP can be diagnostic markers for liver metastases from breast cancer.

Keywords: Liver metastases, breast cancer, prognostic factor, CEA, CA-153, MRI.

Graphical Abstract
[1]
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
[http://dx.doi.org/10.3322/caac.20073] [PMID: 20610543]
[2]
Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008; 14(1): 62-8.
[http://dx.doi.org/10.1097/PPO.0b013e3181629a7b] [PMID: 18303485]
[3]
Cao R, Wang LP. Serological diagnosis of liver metastasis in patients with breast cancer. Cancer Biol Med 2012; 9(1): 57-62.
[PMID: 23691457]
[4]
Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 2003; 89(2): 284-90.
[http://dx.doi.org/10.1038/sj.bjc.6601038] [PMID: 12865918]
[5]
Hamidi O, Tapak L, Jafarzadeh Kohneloo A M. High-dimensional additive hazards regression for oral squamous cell carcinoma using microarray data: A comparative study Biomed Res Int 2014; 2014: 393280.
[6]
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25(33): 5287-312.
[http://dx.doi.org/10.1200/JCO.2007.14.2364] [PMID: 17954709]
[7]
Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 1991; 64(1): 154-8.
[http://dx.doi.org/10.1038/bjc.1991.260] [PMID: 1854615]
[8]
Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 2013; 24(5): 1225-31.
[http://dx.doi.org/10.1093/annonc/mds604] [PMID: 23230137]
[9]
Prabasheela B, Baskaran S, Arivazhagan R. Evaluation of alkaline phosphatase in pre and post operative breast cancer patients Short report Evaluation of alkaline phosphatase in pre and post operative breast cancer patients. Int J Biol Med Res 2012; 3(2): 1536-7.
[10]
Keshaviah A, Dellapasqua S, Rotmensz N, et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18(4): 701-8.
[http://dx.doi.org/10.1093/annonc/mdl492] [PMID: 17237474]
[11]
Crivellari D, Price KN, Hagen M, et al. International (Ludwig) Breast Cancer Study Group (IBCSG). Routine tests during follow-up of patients after primary treatment for operable breast cancer. Ann Oncol 1995; 6(8): 769-76.
[http://dx.doi.org/10.1093/oxfordjournals.annonc.a059314] [PMID: 8589013]
[12]
Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA. Liver metastases from breast cancer: Long-term survival after curative resection. Surgery 2000; 127(4): 383-9.
[http://dx.doi.org/10.1067/msy.2000.103883] [PMID: 10776428]
[13]
Liska V, Holubec L Jr, Treska V, et al. Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer. Anticancer Res 2011; 31(4): 1447-51.
[PMID: 21508401]
[14]
al-Jarallah MA, Behbehani AE, el-Nass SA, et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993; 19(1): 74-9.
[PMID: 8436243]
[15]
Yerushalmi R, Tyldesley S, Kennecke H, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 2012; 23(2): 338-45.
[http://dx.doi.org/10.1093/annonc/mdr154] [PMID: 21543625]
[16]
Huang P, Lan M, Peng AF, et al. Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer. PLoS One 2017; 12(9)e0183835
[http://dx.doi.org/10.1371/journal.pone.0183835] [PMID: 28902911]
[17]
Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone Metastasis Prognostic Factors in Breast Cancer. Breast Cancer (Auckl) 2019; 2019131178223419830978
[http://dx.doi.org/10.1177/1178223419830978] [PMID: 30828246]
[18]
Van Hoof VO, Van Oosterom AT, Lepoutre LG, De Broe ME. Alkaline phosphatase isoenzyme patterns in malignant disease. Clin Chem 1992; 38(12): 2546-51.
[PMID: 1458597]
[19]
Stieber P, Nagel D, Ritzke C, et al. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma. Eur J Clin Chem Clin Biochem 1992; 30(12): 809-14.
[http://dx.doi.org/10.1515/cclm.1992.30.12.809] [PMID: 1489855]
[20]
Ramaswamy G, Rao VR, Krishnamoorthy L, Ramesh G, Gomathy R, Renukadevi D. Serum levels of bone alkaline phosphatase in breast and prostate cancers with bone metastasis. Indian J Clin Biochem 2000; 15(2): 110-3.
[http://dx.doi.org/10.1007/BF02883737] [PMID: 23105250]
[21]
Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer (review). In Vivo (Brooklyn) 1993; 7(613): 607-13.
[22]
Coombes RC, Powles TJ, Gazet JC, et al. Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet 1980; 1(8163): 296-7.
[http://dx.doi.org/10.1016/S0140-6736(80)90790-4] [PMID: 6101748]
[23]
Chandrakanth K, Kpyati A, Murthy DJ. Significance of serum total alkaline phosphatase levels in breast cancer. Int J Clin Biomed Res 2016; 2(1): 13-5.
[24]
Faiz AS, Guo S, Kaveney A, Philipp CS. Venous thrombosis and breast cancer in older women: Racial differences in risk factors and mortality. Thromb Res 2018; 171: 130-5.
[http://dx.doi.org/10.1016/j.thromres.2018.10.002] [PMID: 30296717]
[25]
Lee JH, Lee SW. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterol Res Pract 2017.20177521987
[http://dx.doi.org/10.1155/2017/7521987] [PMID: 28588612]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy